Page last updated: 2024-12-05
3-chloro-2-methylaniline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-chloro-2-methylaniline: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6894 |
| CHEMBL ID | 1570069 |
| SCHEMBL ID | 171322 |
| MeSH ID | M0194823 |
Synonyms (75)
| Synonym |
|---|
| 3-chlor-2-toluidin |
| 3-chloro-2-methylaniline |
| 3-chloro-2-methylphenylamine |
| 2-amino-6-chlorotoluene |
| fast scarlet tr base |
| nsc6184 |
| wln: zr cg b1 |
| 6-chloro-2-aminotoluene |
| o-toluidine, 3-chloro- |
| nsc-6184 |
| benzenamine, 3-chloro-2-methyl- |
| o-methyl-m-chloroaniline |
| azoic diazo component 46 |
| 3-chloro-o-toluidine |
| 87-60-5 |
| scarlet tr base |
| 1-amino-3-chloro-2-methylbenzene |
| 3-chloro-2-toluidine |
| inchi=1/c7h8cln/c1-5-6(8)3-2-4-7(5)9/h2-4h,9h2,1h |
| NCGC00091335-01 |
| nsc 6184 |
| 3-chloro-2-toluidin [czech] |
| 3-chlor-2-toluidin [czech] |
| brn 0471697 |
| toluene, 2-amino-6-chloro- |
| einecs 201-756-6 |
| 6-chloro-ortho-toluidine |
| hsdb 5252 |
| NCGC00091335-02 |
| 3-chloro-2-methylaniline, 99% |
| smr001216563 |
| MLS001056302 |
| AC-11451 |
| AKOS000118880 |
| 3-chloro-2-methyl-aniline |
| A842289 |
| NCGC00091335-03 |
| NCGC00257924-01 |
| dtxcid304815 |
| tox21_200370 |
| cas-87-60-5 |
| dtxsid3024815 , |
| 3-chloro-2-methyl aniline |
| STL168888 |
| 2-methyl-3-chloroaniline |
| 4-12-00-01800 (beilstein handbook reference) |
| qg8lp81715 , |
| unii-qg8lp81715 |
| 3-chloro-2-toluidin |
| ec 201-756-6 |
| FT-0615498 |
| AM20060742 |
| SCHEMBL171322 |
| 3-chloro-2-methylbenzenamine |
| 1-amino-2-methyl-3-chlorobenzene |
| 3-chloro-2-methylphenylamine [hsdb] |
| 6-chloro-2-amino-1-methylbenzene |
| tolfenamic acid impurity b [ep impurity] |
| 3-amino-1-chloro-2-methylbenzene |
| 6-amino-2-chlorotoluene |
| 2-methyl-3-chloro-aniline |
| 1-chloro-2-methyl-3-aminobenzene |
| 3-chloro-2-methyl-phenylamine |
| 3-chlor-ortho-toluidin |
| CHEMBL1570069 |
| W-104012 |
| F2190-0472 |
| mfcd00007766 |
| CS-D1106 |
| 3-chloro-2-methylaniline, technical, >=98.0% (gc) |
| 2-chloro-2-methylaniline |
| Z104474300 |
| AS-44174 |
| Q27287248 |
| EN300-19575 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 35.6032 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.3365 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 37.6505 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 48.9962 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 30.6379 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 28.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.51) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||